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Abstract
Background: Early detection holds the key to an effective control of cancers in general and of oral cancers in
particular. However, screening procedures for oral cancer are not straightforward due to procedural requirements
as well as feasibility issues, especially in resource-limited countries.
Methods: We conducted a cross-sectional study to compare the performance of chemiluminescence, toluidine
blue and histopathology for detection of high-risk precancerous oral lesions. We evaluated 99 lesions from 55
patients who underwent chemiluminescence and toluidine blue tests along with biopsy and histopathological
examination. We studied inter-as well as intra-rater agreement in the histopathological evaluation and then using
latent class modeling, we estimated the operating characteristics of these tests in the absence of a reference
standard test.
Results: There was a weak inter-rater agreement (kappa < 0.15) as well as a weak intra-rater reproducibility
(Pearson’s r = 0.28, intra-class correlation rho = 0.03) in the histopathological evaluation of potentially high-risk
precancerous lesions. When compared to histopathology, chemiluminescence and toluidine blue retention had a
sensitivity of 1.00 and 0.59, respectively and a specificity of 0.01 and 0.79, respectively. However, latent class analysis
indicated a low sensitivity (0.37) and high specificity (0.90) of histopathological evaluation. Toluidine blue had a
near perfect high sensitivity and specificity for detection of high-risk lesions.
Conclusion: In our study, there was variability in the histopathological evaluation of oral precancerous lesions. Our
results indicate that toluidine blue retention test may be better suited than chemiluminescence to detect high-risk
oral precancerous lesions in a high-prevalence and low-resource setting like India.
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Background
Oral malignancies continue to burden the clinical and
economic dimensions of health care around the world
[1,2]. In India, for example, oral cancers constitute 40%
of all cancers and rank as the most common cancer in
men and third most common cancer in women [3,4].
The reason why oral cavity cancers occupy a strategic
position in the health care systems is that an early
detection of these lesions is theoretically possible and
practically useful [5-8]. Such early detection is generally
associated with a high expectation of prevention of
deformity, relapse and mortality [3,9].
Early detection of oral cavity carcinoma is, however,
far from straightforward. Presence of precancerous
lesions is not easy to detect due to a high likelihood of
false-positivity. Histopathology continues to be used as
the reference standard test [10]. However the difficulties
in detecting early lesions with confidence [11] combined
with the possible interrater variations of histopathologi-
cal evaluations [12] compound the diagnostic challenges.
For this reason, light-based methods [9,13,14] that
visually highlight lesions are becoming popular as an
adjunct for detection of precancerous lesions. Despite
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any medium, provided the original work is properly cited.the expected theoretical benefit of these tests, Mehrotra
et al [3] recently reported that these measures may not
add a meaningful value to the simple diagnostic protocol
of a detailed visual examination in a high prevalence set-
ting. It has been argued [15,16] that the light-based
methods are designed for screening rather than as a
diagnostic aid in a tertiary care setting. However, in our
experience and in conjunction with those reported by
Mehrotra et al [3], these tests are currently used as diag-
nostic aids in tertiary care centers in India.
A possible explanation to the contested use of the
light-based protocols for the diagnosis of precancerous
lesions in high prevalence settings could be the variabil-
ity in the histopathological evaluation. Current evalua-
tion of the diagnostic/screening utility of these tests is
contingent upon the assumption that histopathological
evaluation is the reference standard. Arguably, however,
if the histopathological evaluation is itself subject to
errors then the estimates of the sensitivity and specifi-
city of the light-based protocols can be expected to be
biased. In this study, we considered the diagnostic per-
formance of the light-based protocols without treating
histopathological evaluation as a gold standard.
Methods
Study subjects
This study was conducted at the Oral Diagnosis, Medi-
cine and Radiology Department of the Sharad Pawar
Dental College, Sawangi, Maharashtra, India. Consecu-
tive outpatients who visited the study center and who
clinically presented with at least one precancerous lesion
were recruited into this study. The exclusion criteria
were: presence of frank malignancy (class I lesions based
on Sciubba’s [11] definition); known hypersensitivity to
any ingredient or their analogues used during chemilu-
minescent light examination; any systemic disease that
could obscure the true clinical presentation and inter-
fere with or are contraindications to biopsy procedure;
and any dental conditions such as orthodontic appli-
ances or prostheses that may interfere with the
examination.
Study protocol
A pre-enrolment screening questionnaire was used to
record the history regarding the patients’ complaints.
After obtaining written informed consent the patients
were enrolled in the study. The study was approved by
the Ethical Committee of the Datta Meghe Institute of
Medical Science, Wardha (Sawangi), India. Suspicious
lesions were first identified with conventional visual
examination under incandescent projected light and
data including lesion characteristics like the location of
the lesion, the type of lesion, the size, and the presence
or absence of any adjacent satellite lesions were
obtained. This was followed by an oral rinse with 1%
acetic acid solution which was given to the patient to
hold in the mouth for 30-60 seconds before expectorat-
ing. The oral cavity was then examined under conven-
tional incandescent light for any new lesions that
became visible or accentuated after the use of acetic
acid (Figure 1A).
We then conducted two diagnostic tests and docu-
mented the results using one of the following three
diagnostic protocols: chemiluminescent illumination sys-
tem (CHEM, obtained from Vizilite
®, Zila, Inc. Fort Col-
lins, CO), toluidine blue retention test (TBLU) and a
combination of chemiluminescence and toluidine blue
retention test (CHTB, obtained from Vizilite PLus
®,
Zila, Inc. Fort Collins, CO). For CHEM protocol, we
used The Vizilite
® light stick comprising an outer flex-
ible capsule and a retractor (Figure 1B). Upon activation,
the emanating light radiation (wavelength 430-580nm)
was used to examine the oral cavity after dimming the
room lights. The lesions that reflected the blue-white
light were considered CHEM-positive. Any new lesion,
not visible during conventional visual examination
under incandescent light, but visible after chemilumines-
cent illumination test was noted and documented.
For TBLU protocol, the entire oral cavity was swabbed
with 1% acetic acid solution and a pre-soaked swab of
pharmaceutical grade toluidine blue was applied. Excess
toluidine blue was removed using 1% acetic acid. Visual
examination was then repeated under standard incan-
descent light to identify toluidine blue retention (Figure
1C) for each previously identified lesion and/or any new
lesions subsequently found. Dark staining lesions were
considered positive; faint lesions were considered equi-
vocal; and those which did not take up the stain were
considered negative. Using these categories, lesions were
classified as TBLU-positive if it was observed to be posi-
tive and TBLU-negative if the result was either equivo-
cal or negative. Finally, to classify using the CHTB
protocol (Figure 1D), we considered a lesion to be
CHTB-positive if it was both CHEM-positive and
TBLU-positive; otherwise the lesion was considered to
be CHTB-negative. Finally, incisional biopsy was per-
formed on all lesions. All procedures were conducted
during a single patient visit.
Histopathological evaluation
Biopsy specimens were collected in 10% formalin solu-
tion and processed. Histopathologic evaluation was
done by two senior Oral Pathologists blinded to the
clinical findings. The first pathologist evaluated each
specimen at two time points. The average interval
between the two evaluations was 3 months. For all
evaluations, the histopathologists used Smith and Pind-
borg’s [17] scoring system which was based on 13
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0 to 75 and, based on this total score, the histopatho-
logical grading was given as follows: no dysplasia
(score 0-10, Figure 1E), mild dysplasia (score 11-25,
Figure 1F), moderate dysplasia (score 26-45, Figure
1G) and severe dysplasia (score > 45, Figure 1H). We
further reduced these evaluations to a binary classifica-
tion scheme as high risk/low risk in accordance with
the criteria set by the World Health Organization
(WHO) classification [18].
Statistical analyses
We studied the intra-and inter-rater agreement using
Siegel and Castellan’s fixed-marginal multi-rater kappa
statistic, Bland-Altman plot and Pitman’s variance ratio
test for paired observations. The Siegel and Castellan’s
method of kappa estimation permits the estimation of
per category kappa statistic (using the kap command in
the Stata software package). To estimate the diagnostic
performance of histopathological evaluations along with
the three test protocols (CHEM, TBLU and CHTB) we
did not make any ap r i o r iassumption about the refer-
ence standard. Such a representation of the data is
amenable to latent class analysis (LCA) [19-22]. We
used Hui and Walter’s multinomial latent class model,
the details of which are described elsewhere [23]. Briefly,
if there are n dichotomous diagnostic tests, then there
exist 2n + 1 unknown parameters to be estimated (n
sensitivities, n specificities and prevalence) from a total
of 2
n diagnostic combinations. The degrees of freedom
for estimation of the parameters are, thus, 2
n-1. There-
fore this model can be used only if there are at least
three tests (number of parameters to be estimated = 7
and degrees of freedom = 7). When the degrees of free-
dom exceed the number of parameters to be estimated
the excess degrees of freedom can be used to test the
goodness-of-fit of the latent class model. For latent class
analyses, we used the latent1.exe program (Walter and
Cook, personal communication). Other statistical ana-
lyses were conducted using the Stata 10.0 (Stata Corp,
College Station, TX) statistical software package. Statisti-
cal significance was assessed at a type I error rate of
0.05.
Results
We recruited 55 patients with 99 lesions. The character-
istics of the study subjects and the lesions are described
in Table 1. The majority of the study subjects were male
and indulged in chronic tobacco use and/or betel nut
chewing. There were ~70% subjects with two lesions.
Also, 71% of the lesions involved the buccal mucosa
(Table 1).
Figure 1 Study protocol (A-D) and histopathological classification method (E-H). The study protocol included first (A) a regular visual
inspection using standard operating procedures and regular light followed by examination using chemiluminescence (B). This was followed by
application of toluidine blue. The results of toluidine blue retention were seen as dark royal blue coloration (C) or faintly stained blue coloration
(D). Photomicrographs demonstrating the histopathological grading system which classified a lesion as ‘no dysplasia’ (E) if there was no cell
atypia and no changes in architecture; ‘mild dysplasia’ (F) is there was keratosis, mild cellular atypia and architectural changes in the lower third
of epithelium; ‘moderate dysplasia’ (G) if the architectural changes extended to the middle third of the epithelium; and ‘severe dysplasia’ (H) if
there was a marked cellular atypia associated with architectural changes extending through the entire thickness of epithelium. All
photomicrographs show hematoxilin and eosin staining and are depicted at 10× magnification.
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We first considered if there existed intra-rater variability
in the two histopathological evaluations by the same his-
topathologist. For this, we constructed a Bland-Altman
plot on the paired observations provided by the same
histopathologist (Figure 2A) and observed that there
was neither a bias in the histopathologist’s two evalua-
tions nor a significant departure from variability at each
time point as indicated by the Pitman’st e s t .D e s p i t e
t h i s ,h o w e v e r ,t h eP e a r s o n ’s correlation coefficient for
scores at two time points by the same histopathologist
was only 0.28 and the intraclass correlation coefficient
was even lower (rho = 0.03, 95% confidence interval of
rho 0.00-0.13). Together, these findings indicated that
the two histopathological evaluations - even though
from the same histopathologist -effectively behaved as
statistically independent. Therefore, for the ensuing
agreement analyses we treated these two evaluations
and the evaluation by the other histopathologist as three
independent evaluations.
The majority of the specimens were rated as mild by
both the histopathologists (Figure 2B, code 1). We
examined the inter-evaluation agreement for each cate-
gory of the classification. In general, the kappa statistic
was low (< 0.15) for all categories. However, the kappa
statistic reached statistical significance for the mild,
moderate, or severe categories (codes 1, 2, 3, respec-
tively; Figure 2B). The overall agreement among the
three evaluations was also low but statistically significant
(kappa = 0.1126, p = 0.005). Together, these findings
indicated a substantial intra-and inter-rater variability in
the histopathological evaluations of the study specimens.
Composite histopathological evaluation
Thus, we reasoned that the true histopathological evalua-
tion for a given specimen would remain unknown. To use
LCA, we needed to binarize the histopathological classifi-
cation as shown in Figure 2C. Using this binarization
scheme, we constructed eight combinatorial categories
based on each histopathological evaluation (Figure 2D).
The results of the LCA indicated that the estimated preva-
lence of the latent trait of a high-risk lesion was 20.8%.
LCA predicted that the sensitivities of the three evalua-
tions were 95.4%, 87.2%, and 71.4%, respectively, while the
respective specificities were 50.4%, 63.1%, and 59.6%.
Using these predictions, LCA estimated that the probabil-
ity of a high-risk lesion was lowest when all the histo-
pathological evaluations classified a specimen as a low-risk
lesion, and highest when all the evaluations classified it as
a high-risk lesion (bar graph in Figure 2D).
We then proceeded to evaluate the validity of a com-
posite histopathological outcome. For this, we first gen-
erated the sum of codes ascribed to each specimen by
all the three evaluations with the expectation that speci-
mens with higher sums of scores (range 0-9) will have a
higher likelihood of high-risk lesions. That indeed was
t h ec a s e( F i g u r e2 E ) .O n e - w a ya n a l y s i so fv a r i a n c ei n d i -
cated that the total score explained 87.1% of the varia-
bility in the estimated probability of a high-risk lesion
based on LCA. We then generated the majority vote
from the three histopathological evaluations as follows:
a lesion received as the histopathological majority vote
(HPMV) the risk score seen in two or three evaluations.
If all three evaluations yielded a different risk score for
the same lesion then average risk score was taken as the
HPMV. Using this composite measure, we observed that
17% specimens had a high-risk lesion (Figure 2F). This
number corroborated the estimated prevalence of latent
high-risk lesion trait using LCA.
Comparison of diagnostic performance
We first compared the diagnostic performance of the
three test protocols (CHEM, TBLU and CHTB) using
the histopathological majority vote (HPMV) as the refer-
ence standard. We observed ( 2, column titled “Com-
pared to HPMV”) that CHEM had no specificity while
Table 1 Characteristics of the study subjects and samples
Characteristic N
† or Mean* %
† or SD*
Age (y) 44.4 17.1
Gender
Males 51 92.7
Females 4 7.3
Personal habits
Tobacco use
Tobacco 16 29.1
Tobacco + lime 33 60.0
Snuff 2 3.6
Betel nut
Smoking 35 63.6
Bidi 6 10.9
Cigarettes 2 03.6
Alcohol 11 20.0
Number of samples
1 14 25.5
2 38 69.1
3 3 5.5
Location of lesion
Tongue 5 5.1
Palate 1 1.1
Buccal mucosa 70 70.7
Buccal vestibule 10 10.1
Commensural Mucosa 7 7.1
Retromolar area 1 1.0
Labial vestibule 5 5.1
†, for categorical variables; *, for continuous variables; SD, standard deviation;
y, years
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CHTB. We then conducted LCA for all the four dichot-
omous diagnostic test protocols. Considering the combi-
natorial results of the four test protocols together, we
observed that (Table 2) the estimated prevalence of
high-risk lesions in our study sample was 27.3% (95 CI
18.2%-36.3%). Interestingly, we observed that the histo-
pathological majority vote had a high specificity but a
low sensitivity. On the other hand, toluidine blue, alone
or with chemiluminescence, had near-perfect sensitivity
as well as specificity. Chemiluminescence alone had very
low specificity. The overall goodness-of-fit of our LCA
model was very good (c
2 = 0.24, degrees of freedom =
6, p = 0.99).
Discussion and Conclusions
We made three cardinal observations. First, for detec-
tion of precancerous lesions, there exists substantial
Figure 2 Variability in the evaluation of precancerous lesions on histopathology. (A) Intra-rater agreement on the Smith and Pindborg’s
scores at two time points spaced 3 months apart. The chart shows difference versus average Bland-Altman plot and the dotted lines represent
the mean and 95% confidence interval for the difference. Pitman’s P, significance value for difference in variability in two observations obtained
using Pitman’s variance ratio test. (B) Three histopathological evaluations (H1-H3) were available for each specimen. Two evaluations (H1 and H2)
were contributed by the same pathologist at two different time points, while the third evaluation (H3) was contributed independently by a
second histopathologist. Each lesion was classified as no (code 0), mild (code 1), moderate (code 2) or severe (code 3) dysplasia. These codes
correspond to the Figure 1, panels E through H, respectively. Table shows the number of subjects classified based on each evaluation. Bar chart
to the right shows the within-outcome category agreement using the kappa statistic. P, significance value of the kappa statistic. (C) Strategy
used for dichotomization of the histopathology results. The colors match those in panel D. (D) Combinatorial representation of the three
histopathological evaluations for latent class analyses. N, number of subjects. Bar chart to the right shows the estimated probability of a high-risk
lesion (H) for given combination of the three histopathological evaluations. (E) Bar chart showing the association between total histopathological
score and the estimated probability of a true high-risk lesion. No study subject had a score of 0, 8 or 9. (F) Pie chart showing the proportion of
subjects classified as high risk (pink sector) or low risk (yellow sector) based on majority vote from the three histopathological evaluations.
Ujaoney et al. BMC Clinical Pathology 2012, 12:6
http://www.biomedcentral.com/1472-6890/12/6
Page 5 of 7intra-rater and inter-rater variation in the histopatholo-
gical evaluation. Our results suggest that histopathology
may be useful as a diagnostic test in demonstrably high
degree of dysplasia or frank neoplasia but its value as a
reference standard for diagnosis of low-risk precancer-
ous lesions is questionable. Consequently, the use of his-
topathology as a reference standard against light-based
assistance for diagnosis of high-risk lesions may lead to
biased estimates of the diagnostic performance of these
measures.
Second, we observed widely differing estimates of the
sensitivity and specificity of the studied diagnostic pro-
tocols. However, caution needs to be exercised when
reading and interpreting the results of latent class mod-
eling [24-27]. A substantially different estimate of sensi-
tivity (or specificity) for a test from that for the other
tests can result from two scenarios: a) if the test is diag-
nostically inferior as compared to the rest; and b) if the
test is using different criteria for classification of the dis-
ease state. In our case, the results do not necessarily
imply that TBLU and CHTB are diagnostically superior
to histopathology - rather it is possible that these tests
use totally different criteria that do not compare with
those used by histopathology. Nevertheless, our results
clearly demonstrate (Table 2) that one of the main rea-
sons for the controversial estimates of the diagnostic
performance of light-based aids may be the classification
method employed for the reference standard.
Third, a comparison of the diagnostic performance of
TBLU and CHTB consistently indicated that use of
CHEM may be somewhat redundant. From a primary
health care perspective this finding is important since it
will reduce the cost of diagnostic evaluation consider-
ably by restricting the use of the more expensive com-
ponent. Indeed the estimates of sensitivity and
specificity of TBLU observed in this study are compar-
able with or better than those of other more expensive
protocols like autofluorescence [28,29], photodynamic
diagnosis [30], and chemiluminescence [31]. Our results
are in agreement with the findings of Epstein et al
which show that toluidine blue retention test holds pro-
mise as a screening tool for high-risk oral precancerous
lesions since it can reduce a large number of unneces-
sary biopsies [32]. Concurring with other studies [33,34],
our results encourage consideration of TBLU as a viable
and feasible screening method in high-prevalence and
low-resource scenarios like India.
There are important limitations of this study. First, as
with the Mehrotra et al [3] study, our study recruited
patients with a suspicion of a precancerous lesion for
the reasons of feasibility as observed elsewhere [35].
However, the protocol did preclude visually negative
patients that could have been later detected by at least
one of the diagnostic methods. Our estimates of high
sensitivity may also partially reflect this spectrum bias
thereby limiting a ready generalization of the results.
Second, the study sample had an a priori high likelihood
of a precancerous lesion. Therefore our study design
does not permit a full evaluation of the screening per-
formance of these tests but rather considers them in the
more practical scenario of a tertiary care setting as a
diagnostic aid.
In summary, our findings support those of Mehrotra
et al [3] and demonstrate that improvements are needed
for histopathological evaluation of precancerous lesions
- especially, low risk lesions. Our findings also suggest
that toluidine blue retention may be considered as a
diagnostic strategy for oral cancers in countries like
India. More robust and larger studies are required to
assertively and definitively answer questions related to
the screening use of these tools in high prevalence
settings.
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Table 2 Diagnostic performance of the tests for high-risk
lesions
Protocol Parameter Compared to HPMV Using LCA
CHEM Sensitivity 1.00 (0.82-1.00) 1.00 (0.99-1.00)
Specificity 0.01 (0.00-0.06) 0.01 (0.00-0.04)
TBLU Sensitivity 0.59 (0.36-0.78) 0.99 (0.92-1.00)
Specificity 0.79 (0.69-0.87) 1.00 (0.99-1.00)
CHTB Sensitivity 0.59 (0.36-0.78) 1.00 (0.99-1.00)
Specificity 0.78 (0.68-0.86) 1.00 (0.99-1.00)
HPMV Sensitivity — 0.37 (0.19-0.55)
Specificity — 0.90 (0.83-0.97)
Prevalence of HRL 0.17 (0.10-0.24) 0.27 (0.18-0.36)
CHEM, chemiluminescence; TBLU, toluidine blue retention; CHTB, toluidine
blue retention and chemiluminescence; HPMV, histopathology majority vote;
LCA, latent class analysis; HRL, high risk lesion
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